Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type ... ( DEERFIELD Ill. and OSAKA Japan ...)

HOME >> MEDICINE >> TECHNOLOGY

Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes

Date:9/4/2009

DEERFIELD, Ill. and OSAKA, Japan, Sept. 4 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl). The FDA informed Takeda on June 26, 2009 that further review of the alogliptin monotherapy NDA would be conditional based upon additional data from a cardiovascular (CV) safety study that satisfies the statistical requirements of the December 2008 FDA Guidance titled, "Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes."

"This complete response letter from the FDA is consistent with the June 26 complete response letter for alogliptin, a key component of the alogliptin and ACTOS fixed-dose combination product," said Nancy Joseph-Ridge, M.D., general manager, Pharmaceutical Development Division. "The FDA recently agreed to the study design for a cardiovascular outcomes trial for alogliptin, titled EXAMINE, and patient enrollment is planned to begin this month. We anticipate that the EXAMINE trial will provide the FDA with the information needed to continue the NDA reviews of both the alogliptin monotherapy and the alogliptin and ACTOS fixed-dose combination."

The complete response letter was specific to the FDC of alogliptin and ACTOS, and did not include any new questions or concerns about alogliptin or ACTOS.

About ACTOS(R) (pioglitazone HCl)

ACTOS is a prescription medication used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for patients with type 1 "juvenile" diabetes or diab
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
2. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
3. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
4. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
5. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
6. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
7. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
8. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
9. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
10. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
11. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials

Post Your Comments:

(Date:2/9/2010)... -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ... tender offer for all outstanding shares of common stock ... offer and withdrawal rights expired at 12:00 midnight, ... 2010 . The depositary for the tender offer has ... 18,611,072 shares of Chattem common stock (including approximately 2,853,283 ...

(Date:2/8/2010)... Feb. 8 Rapid developments in ... increase in the use and cost of "specialty" ... and psoriasis. This has led to some inappropriate ... and medication coverage being spread over both pharmacy ... solution with Medication Cost Integration (MCI), which covers ...

(Date:2/8/2010)... 8 Transgenomic, Inc. (OTC Bulletin ... a preliminary study with a leading pharmaceutical company ... technology to detect colorectal tumor-associated KRAS mutations that ... detected in plasma samples in which the mutation ... DNA analysis methodologies such as Sanger sequencing. ,, ...

Breaking Medicine Technology:Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc. 2 Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc. 3 Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc. 4 Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc. 5 RegenceRx Leads the Industry With Introduction of Medication Cost Integration 2 RegenceRx Leads the Industry With Introduction of Medication Cost Integration 3 Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR 2 Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR 3 Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR 4 26quot 3BJesse 26apos 3Bs Story 26quot 3B to Open The 10th Annual Malibu Film Festival 53500 1 26quot 3BJesse 26apos 3Bs Story 26quot 3B to Open The 10th Annual Malibu Film Festival 53500 2 26quot 3BJesse 26apos 3Bs Story 26quot 3B to Open The 10th Annual Malibu Film Festival 53500 3 U S Fund for UNICEF and Major League Soccer Kick Off Partnership to Save Childrens Lives 53499 1 U S Fund for UNICEF and Major League Soccer Kick Off Partnership to Save Childrens Lives 53499 2 U S Fund for UNICEF and Major League Soccer Kick Off Partnership to Save Childrens Lives 53499 3 Leading U S Expert Offers Ten Warning Signs and Symptoms of Mental Health Problems in Elderly 53497 1 Leading U S Expert Offers Ten Warning Signs and Symptoms of Mental Health Problems in Elderly 53497 2 Leading U S Expert Offers Ten Warning Signs and Symptoms of Mental Health Problems in Elderly 53497 3

[0] Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.[0] RegenceRx Leads the Industry With Introduction of Medication Cost Integration [0] Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR

... Study Also Showed Arzoxifene Significantly Suppressed Bone Turnover ... Greece, March 23 Eli Lilly and Company ... showing arzoxifene, an investigational selective estrogen receptor modulator ... mineral density (BMD) in the lumbar spine, total ...

... YORK, March 20 InnoCentive, Inc., ... Publishing Group (NPG) , a leading scientific and ... greater scientific collaboration and open innovation.Under the agreement, ... the involvement of scientists worldwide in solving global ...

Other Medicine Technology:Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 2 Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 3 Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 4 Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 5 InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation 2 InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation 3 InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation 4

Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation

(Date:2/9/2010)... WEST PALM BEACH, Fla. , Feb. 9 /PRNewswire-USNewswire/ ... a grant awarded to the School District of Palm ... eat right and get fit. The Robert Wood Johnson Foundation ... opportunities for physical activity and access to affordable healthy foods ... and Palm Springs communities. Based on a rigorous ...

(Date:2/9/2010)... iPhone application created by UH researchers is providing ... world. Those annual rankings of America,s fattest and ... host of indirect indicators may soon have a ... the University of Houston provides objective data. , ... from Apple,s "App Store," allows users to keep ...

(Date:2/9/2010)... increased in infants born prematurely in the US, according ... System (LUHS). These findings were reported at the 30th ... Chicago. They also were published in the latest issue ... . , Researchers reported that CP is associated with ... This inflammation is more common in premature births from ...

(Date:2/9/2010)... type II audit is a significant achievement and differentiates ... , ... (PRWEB) February 9, 2010 ... announced that it has successfully completed a Statement on Auditing ... by McGladrey & Pullen, LLP and covered Hallmark Insights operational ...

(Date:2/9/2010)... men with fewer complications, study finds , , TUESDAY, Feb. ... are more likely than men to fail catheter ablation ... procedures five times as often as women and usually ... February issue of HeartRhythm Journal , are based ... and 2008. They underwent pulmonary vein antrum isolation, a ...

Breaking Medicine News(10 mins):Health News:Planting Seeds to Fight Childhood Obesity 2 Health News:Phone app providing real-time statistics on physical activity around the world 2 Health News:Phone app providing real-time statistics on physical activity around the world 3 Health News:Incidence of cerebal palsy on rise in United States 2 Health News:Hallmark Insights Completes SAS 70 Type II Audit 2

[0] Planting Seeds to Fight Childhood Obesity [0] Phone app providing real-time statistics on physical activity around the world [0] Incidence of cerebal palsy on rise in United States [0] Hallmark Insights Completes SAS 70 Type II Audit [0] Women More Likely to Fail Treatment for Atrial Fibrillation

... Three studies to be presented at Teenage Cancer Trust,s Fifth ... (Monday) have thrown light on the extent of delays that ... with cancer, and on some of the reasons why this ... Cancer at the University of Manchester, UK, will tell the ...

... to 75 with type 2 disease have same odds for condition, ... adults with type 2 diabetes run much less risk than previously ... to the heart, according to a new study. , ... diabetes run the same risk of having a cardiac condition whether ...

... presenting with one checked for other , , SATURDAY, ... between type 2 diabetes and obstructive sleep apnea (OSA) ... the International Diabetes Federation warns. , Up to 40 ... also have diabetes, recent studies suggest. Likewise, more than ...

... Echocardiography System to Acquire, Instantaneous, Non-Stitched Full-Volume Images of the ... ... Heartbeat, TORONTO, June 7 Siemens Healthcare, (http://www.usa.siemens.com/healthcare ) ... the world to acquire,non-stitched, real-time full-volume 3D images of the heart ...

... Event Becomes "Susan G. Komen GLOBAL Race for ... National Mall was,passionately pink this morning, as nearly ... for the 19th annual Susan,G. Komen National Race ... to fund breast cancer research and community health ...

... Renhuang,Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or "the ... of China ("PRC"),today announced the successful completion of ... May 29, 2008., Tianma pills, one of ... the treatment of headaches. The primary,active ingredient in ...

Other Medicine News:Health News:Teenagers and young adults with cancer can face long delays before finally being diagnosed 2 Health News:Teenagers and young adults with cancer can face long delays before finally being diagnosed 3 Health News:Teenagers and young adults with cancer can face long delays before finally being diagnosed 4 Health News:Older Diabetics' Risk of Cardiac Ischemia Lower Than Thought 2 Health News:Doctors Urged to Look for Link Between Type 2 Diabetes, Sleep Apnea 2 Health News:Siemens' New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography 2 Health News:Siemens' New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography 3 Health News:19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area 2 Health News:19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area 3 Health News:Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent 2 Health News:Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent 3

Teenagers and young adults with cancer can face long delays before finally being diagnosed Older Diabetics' Risk of Cardiac Ischemia Lower Than Thought Doctors Urged to Look for Link Between Type 2 Diabetes, Sleep Apnea Siemens' New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography 19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent

Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....

2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....

... Off-white free flowing powder. pH: pH(4.7%, ... Casein Peptone: 24% Yeast Extract: 47% Potassium Phosphate ... To Use: Dissolve 47 gm powder per liter ... of plasmid DNA and recombinant proteins than LB ...

...

Medicine Products:

LB Broth Inoculum Broth with Calcium Chloride Terrific Broth, Ready-Made Powder TERRIFIC BROTH

Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type ...( DEERFIELD Ill. and OSAKA Japan ...),Health